Efficacy in Japanese adults with growth hormone deficiency receiving weekly somapacitan or daily growth hormone: results from phase 3 REAL 1 trial.
Saved in:
| Title: | Efficacy in Japanese adults with growth hormone deficiency receiving weekly somapacitan or daily growth hormone: results from phase 3 REAL 1 trial. |
|---|---|
| Authors: | Otsuka F; Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan., Rasmussen MH; Clinical Drug Development, Novo Nordisk A/S, Søborg, Denmark., Endo T; Medical Affairs Department, Novo Nordisk Pharma Ltd., Tokyo, Japan., Sværke C; Clinical Drug Development, Novo Nordisk A/S, Søborg, Denmark., Tahara S; Department of Neurological Surgery, Nippon Medical School, Musashikosugi Hospital, Kawasaki City, Kanagawa, Japan., Johannsson G; Department of Internal Medicine and Clinical Nutrition, Institute of Medicine at Sahlgrenska Academy, University of Gothenburg and Department of Endocrinology, Diabetology, and Metabolism, Sahlgrenska University Hospital, Göteborg, Sweden. |
| Source: | Frontiers in endocrinology [Front Endocrinol (Lausanne)] 2025 Feb 07; Vol. 16, pp. 1534891. Date of Electronic Publication: 2025 Feb 07 (Print Publication: 2025). |
| Publication Type: | Journal Article; Clinical Trial, Phase III; Randomized Controlled Trial; Multicenter Study; Clinical Trial, Phase I |
| Journal Info: | Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101555782 Publication Model: eCollection Cited Medium: Print ISSN: 1664-2392 (Print) Linking ISSN: 16642392 NLM ISO Abbreviation: Front Endocrinol (Lausanne) Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1664-2392 |
|---|---|
| DOI: | 10.3389/fendo.2025.1534891 |
